Polymorphisms in genes coding for drug metabolizing enzymes, such as the cytochrome P450 enzymes CYP2C19 and CYP2D6, can lead to therapy failure and side effects. In earlier studies, the novel variant CYP2C19*17 increased metabolism of several CYP2C19 substrates. The objective of this study was to evaluate the impact of CYP2C19*17 on the metabolism of amitriptyline (AT), citalopram (CIT), and clomipramine (CLOM). Six-hundred and seventy-eight patients were included in this study, based on availability of DNA and serum levels of parent drug and main metabolite. We investigated the relationship between CYP2C19 genotypes and metabolic parameters, including serum levels corrected for dose and metabolic ratio (MR).
Introduction
Although a wide range of different drug classes is available, about 30-50% of patients will not respond satisfactorily to treatment with standard psychiatric medication. Part of the variation in response and adverse effects is attributed to interindividual differences in metabolic activity. Cytochrome P450 (CYP450) enzymes are involved in the metabolism of many drugs, the family members CYP2C19 and CYP2D6 account for the metabolism of 30-40% of all medicine. Many studies have shown clear correlations between metabolic ratios (MRs) of psychotropics and CYP2C19 and CYP2D6 genotypes. [1] [2] [3] [4] [5] [6] [7] [8] More than 20 polymorphisms have been described for CYP2C19. 9 In Caucasians, the homozygous presence of the non-functional CYP2C19*2 allele accounts for 75-93% of poor metabolizers. The higher percentage of Asian poor metabolizers is attributed to the non-functional CYP2C19*3 variant. 10 As a substantial part of the interindividual differences in CYP2C19 activity can be explained by polymorphisms of CYP2C19, genotyping of CYP2C19 could potentially increase treatment efficacy of CYP2C19-dependent drugs. However, subjects carrying neither the CYP2C19*2 nor CYP2C19*3 allele still show large interindividual differences in CYP2C19 activity. Part of these differences might be caused by the polymorphism CYP2C19*17, which increased CYP2C19 expression levels in vitro. 11 Moreover, the CYP2C19*17 polymorphism has been associated with increased metabolism of omeprazole, escitalopram, and imipramine. [12] [13] [14] The main metabolic pathway of citalopram (CIT) is demethylation into desmethyl-CIT (DCIT) by CYP2C19, CYP3A4, and CYP2D6 ( Figure 1) . 1, [15] [16] [17] [18] [19] The metabolite DCIT, which is about 10 times less active than CIT itself, is metabolized into didesmethyl-CIT by CYP2D6. 15, 19 The main metabolic pathway of the active drug amitriptyline (AT) is demethylation to the active metabolite nortriptyline (NT) by CYP2C19 and subsequent hydroxylation to 10-hydroxy-NT by CYP2D6 (Figure 1) . 3, [20] [21] [22] [23] [24] Clomipramine (CLOM) is demethylated into N-desmethyl-CLOM (DCLOM) by several CYP450 enzymes, including CYP2C19, CYP3A4, and CYP1A2. 25, 26 Hydroxylation of the active metabolite DCLOM is catalyzed by CYP2D6 (Figure 1) . [25] [26] [27] AT, CIT, and CLOM are frequently prescribed antidepressants in the Psychiatric Hospital Meerkanten (Ermelo, the Netherlands). Together, they represent one-third of all antidepressants prescribed in this institute. We set out to assess the additional value of CYP2C19*17 genotyping in a psychiatric setting. Data on serum levels of AT, CIT, and CLOM and their main metabolites were collected. Several metabolic parameters were tested for association with CYP2C19*17, including MR and serum level corrected for dose (C/D), providing information on the extend in which CYP2C19*17 influences the metabolism of the three antidepressants. Furthermore, the number of patients outside therapeutic range were investigated to provide more direct information on the clinical consequences of CYP2C19 polymorphisms, in particular CYP2C19*17.
Materials and methods

Patients
All adult patients of the Psychiatric Hospital Meerkanten (Ermelo, the Netherlands) treated with AT, CIT, and/or CLOM in the period 1998-2008 for which both data on serum levels of parent drug, serum levels of main metabolite (NT, DCIT, and DCLOM, respectively), and DNA samples were available were included in this study (n ¼ 678). Information on age, gender, CYP2D6 genotype, presence of CYP2C19*2, and serum levels of antidepressant were collected. To allow correction of serum levels for dose, data on prescribed daily dose of AT, CIT, or CLOM were collected for the days preceding blood collection. Information on daily dose was available for 460 patients. Information on comedication was not collected. The use and publication of data on medication, CYP2C19, and CYP2D6 genotype and serum levels for research purposes has been approved by the psychiatric hospital's research board. For this study, patients were not subjected to any procedures besides routine clinical practice. Patients are informed on the use of data for research purposes, and data are excluded from research on objection.
CYP2C19 and CYP2D6 genotyping
Patients were routinely screened for CYP2C19*2, CYP2D6*3, *4, *5, *6, and multiplication. Blood was collected in the anticoagulant EDTA. DNA was isolated using the QIAamp DNA Blood MiniKIT (Qiagen, Hilden, Germany). Anonimized DNA samples and whole blood were routinely stored at À70 1C for research purposes. CYP2C19*2, CYP2D6*3, *4, and *6 determinations were performed as single-tube tetraprimer assays using two control primers and two allelespecific primers (see Supplementary Appendix A and B). PCR reactions were performed using 50-250 ng DNA, 0.2 mM dNTPs, 1.0-2.5 U Thermoprime Plus DNA polymerase (Abgene House, Epsom, UK) and 1.0-1.7 Â ReddyMix PCR buffer in a final volume of 25 ml. PCR products were visualized by agarose gel electrophoresis. To detect CYP2C19*17, a real-time allelic discrimination assay was developed. On the basis of a publication by Sim et al.,
11 a 470 base pair region of the CYP2C19 promotor was amplified using the primer pair CYP2C19-forward and CYP2C19-reverse (see Supplementary Appendix A for primers, probes and PCR cycling conditions). Since November 2007, detection of CYP2C19*2 was performed by melt-curve analysis (see Supplementary Appendix A for primers, probes, and PCR cycling conditions). This melt-curve analysis assay was developed in the laboratory of Twente Hospital (ZGT) by A de Vos and Dr RGHJ Maatman (unpublished data). In addition, since November 2007, detection of CYP2D6*3, *4, and *6 was performed using real-time allelic discrimination assays (see Supplementary Appendix B for primers, probes and PCR cycling conditions). These real-time assays were also developed in the laboratory of Twente Hospital (ZGT) by A de Vos and Dr RGHJ Maatman (unpublished data). All real-time allelic discrimination assays and melt-curve assays were performed using 20-50 ng DNA, 0.2 mM dNTPs, 1.25 U Taq Full Hot Start DNA Polymerase (Clontech Laboratories, Mountain View, CA, USA) and 1 Â PCR buffer in a final volume of 25 ml. Amplification, detection, and melt-curve analysis were performed using the Rotorgene 6000 cycler (Corbett, San Francisco, CA, USA). Detection of CYP2D6 deletion and multiplication (CYP2D6*5 and CYP2D6xN, respectively) was performed using 50-150 ng DNA, 0.36 mM dNTPs, 1.35 mM Mg(OAc) 2 , 1.3 U rTth DNA Polymerase XL (Applied Biosystems, Carlsbad, CL, USA) and 0.9 Â 3.3xXL Buffer II (see Supplementary Appendix B for primers and PCR cycling conditions). PCR products were visualized by agarose gel electrophoresis. All routinely performed assays were validated using references samples and were subject to regular external quality controls. Reference samples CYP2C19*1/*1, *1/*17, and *17/*17 to validate the CYP2C19*17 assay were kindly provided by Dr RHN van Schaik (Erasmus MC Rotterdam, the Netherlands).
HPLC
Therapeutic drug monitoring was routinely performed for all patients. Blood samples for TDM were drawn 12-16 h post-medication to ensure measurement of trough medication levels at steady state. Serum was stored at À20 1C within 6 h of collection. Serum levels of AT, CIT, and CLOM and their metabolites were determined by HPLC within 14 days of collection. Liquid-liquid extraction was performed with heptane/ethylacetate/isoamylalcohol/2 M NaOH (157:40:3:16 vol/vol/vol/vol) solution (AT and CLOM) or with di-isopropylether/isoamylalcohol/2 M NaOH (99/1/8 vol/vol/vol) solution (CIT). Concentrations of AT, CLOM, and their metabolites were determined using a Chromsper guardcolumn (SS 10 Â 2 mm, silica) and two in tandem Chromsper 5Si cartridge columns (100 Â 3 mm, 5u) (Varian, Palo Alto, CA, USA) with ethanol/water/tertbutylamine (200:50:0.06 vol/vol/vol) as the mobile phase, flow rate 0.5 ml min -1 , UV detection at 254 nm. Since 2007, concentrations of AT, CLOM, and their metabolites were analyzed on a Inertsil ODS 3 column (150 cm Â 4.6 mm, 4u) (Aurora Borealis Control) with 67 mM KH 2 PO 4 pH 3/ acetonitrile (130/70 vol/vol) as the mobile phase, flow rate 0.8 ml min -1 (AT) or 1.3 ml min -1 (CLOM), UV detection at 254 nm. This method was an adaptation of a method described by Aymard et al. 28 The two methods produced comparable concentration values. Concentrations of CIT and metabolite were determined by analysis of samples on a Hypersil BDS C18 column (100 cm Â 4.6 mm, 3u) (Aurora Borealis Control) with 50 mM KH 2 PO 4 pH 3.7/acetonitrile (70/30 vol/vol), flow rate 0.8 ml min -1 , UV detection at 240 nm. This method was an adaptation of a method described by Rop et al. 29 Internal standards were protriptyline (AT), amitriptyline (CLOM), and desmethylclozapine (CIT). Detection limits were 5 mg l -1 for AT, CLOM, and metabolites, and 1 mg l -1 for CIT and metabolite. Validation was performed comparing intra-assay values (samples of patients with low, medium, and high serum levels measured 10 Â within one assay) and inter-assay results (measuring samples of patients with low, medium, and high serum levels 6-7 Â in independent assays). Variance coefficient values were 0.1 (both intra-and inter-assay) for AT and CLOM and 0.04 (intra-assay) and 0.06 (inter-assay) for CIT. Reference samples were obtained from the Dutch Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology (KKGT). The assays were subjected to regular external quality controls.
Chemicals
The HPLC purified primers and probes used in real-time PCR were supplied by Biolegio, the Netherlands. All other primers were supplied by Sigma-Aldrich, St Louis, MO, USA. Primer and probe stocks (100 mM in water) were stored at À20 1C. 
Statistics
Statistical analyses were performed using SPSS for Windows (SPSS version 15.0, Chicago, IL, USA). Cases were grouped according to genotype. A subset of data showed a significant difference in variances, a lack in normality of residuals, and large differences in sample size. Transformation to log values did not eliminate these difference in variances and residuals. Therefore, data were analyzed with the non-parametric Mann-Whitney to test the significance of differences between mean values of a specific subgroup and the preceding subgroup, as well as the reference subgroup (CYP2C19*1/*1 and/or CYP2D6*1/*1). MRs were calculated as the ratio between steady-state concentrations of parent drug (AT, CIT, or CLOM) and the main metabolite (NT, DCIT, and DCLOM, respectively). For each patient, the average of all MRs and C/ Ds available were used. Group averages were calculated using the averages for individual patients. The study population was divided into six subgroups based on CYP2C19 genotype (*1/*1, *1/*17, *17/*17, *1/*2, *2/*2, and *2/*17). Association studies with respect to CYP2D6 genotype were performed using the semi-quantitative gene dose (SGD) system. 3 A value of 0 was appointed to non-functional alleles (CYP2D6*3, *4, *5, *6, and *4xN), a value of 1 to functional alleles (CYP2D6*1) and a value of 2 to gene multiplication of functional alleles (CYP2D6*1xN). The SGD value is the sum of values of both alleles, resulting in four subgroups (SGD ¼ 0, 1, 2, and 3). Patients with gene duplication in combination with alleles that differ in functionality (for example (CYP2D6*1/*4)xN), were excluded, as these patients could not be assigned to a specific SGD group.
CYP2C19*17 and metabolism of antidepressants Results
Group characteristics and CYP2C19*17 allele frequency A total of 678 adult patients using AT, CIT, or CLOM were included in this study. Patients were screened for CYP2C19*17 using a real-time PCR method and data on CYP2C19*2 and CYP2D6 genotype were collected. Genotype frequencies and group characteristics are shown in Table 1 . The overall allele frequency of CYP2C19*17 was 0.22. The frequency of CYP2C19*17 observed in this Dutch population of psychiatric patients is similar to the frequencies observed in Polish peptic ulcer patients (0.27) and in Swedish (0.18), Norwegian (0.22), and Ethiopian (0.18) psychiatric patients, but higher than the frequency observed in Chinese psychiatric patients (0.04). 11, 12, 30 Increased age was associated with increased MR, increased C/D, and decreased daily dose for AT, CIT, and CLOM (data not shown). The relationship between parent drug concentration and dose was non-linear for AT, CIT, and CLOM; a trend was observed for higher levels with higher dose, whereas the C/D value decreased with increased doses (data not shown).
Amitriptyline
A total of 150 patients were included in the association study for AT. Information on daily dose was available for 86 patients. The presence of CYP2C19*17 was associated with lower AT levels and MR AT/NT values (Table 2; Figure 2 ). This association did not reach significance. The presence of CYP2C19*2 was significantly associated with higher AT levels and MR AT/NT values. No significant associations were observed between CYP2C19 genotype and NT levels, AT þ NT levels, C/D values or daily dose. CYP2D6 genotype affected AT metabolism in earlier studies, as well as in this study (see Supplementary Appendix C, 3, 23 ). Therefore, the study population was grouped based on both CYP2C19 and CYP2D6 genotype ( Table 3 ). The association of CYP2C19*17 with MR AT/NT reached significance within the CYP2D6*1/*1 subgroup (SGD ¼ 2). The sum of the active compounds AT and NT is used to follow-up AT therapy. CYP2C19 genotype did not significantly affect the proportion of subjects with AT þ NT serum levels below therapeutic range (100-300 mg l -1 ) ( Table 3 ). The concentration of the active metabolite NT, rather then AT itself, has been associated with side effects of AT therapy. 22 Both CYP2C19*17 and CYP2D6 non-functional alleles were significantly associated with higher proportion of patients with NT serum levels above therapeutic range (50-150 mg l -1 ).
Citalopram
Group characteristics of the 338 patients included in the association study for CIT are shown in Table 4 . Information on daily dose was available for 223 patients. The presence of CYP2C19*17 was significantly associated with lower MR CIT/DCIT values, whereas the presence of CYP2C19*2 was significantly associated with higher MR CIT/DCIT values and Number of subjects is restricted to subjects for which information on daily dose was available.
c Significantly different from preceding CYP2C19 subgroup (Po0.05). Figure 2 ). Strikingly, the subgroup CYP2C19*2/*2 showed significantly higher mean dose compared with CYP2C19*1/*1. Though this mean value is based on four subjects, it might indicate unsatisfactory response at lower doses, leading to increased doses in an attempt to obtain a more satisfactory response. No significant differences were observed between CYP2C19 genotype and CIT levels, but higher CIT levels did correlate with decreasing predicted activity (as predicted from genotype) ( Table 4) . The relationship between CYP2C19 genotype and CIT levels was also reflected in the proportion of patients with serum levels outside therapeutic range (30-130 mg l -1 ). The CYP2C19*17 allele was significantly associated with lower proportions of patients with CIT levels above therapeutic range (Table 4) . No significant associations were observed between CYP2C19 genotype and DCIT levels. CYP2D6 has been shown in earlier studies to metabolize both CIT and DCIT (Figure 1) . 31 In this study, increasing SGD values were significantly associated with decreasing levels of both CIT and DCIT (see Supplementary Appendix D). Significantly different from CYP2C19 subgroup CYP2C19*1/*1 (Po0.05). e Shown in brackets is the number of subjects outside therapeutic range/total number of subjects. Table 5 . The mean age of subgroup CYP2C19*17/*17 was significantly lower compared with the other genotype groups (data not shown). Information on daily dose was available for 151 patients. The presence of CYP2C19*17 was not significantly associated with the majority of the variables investigated; the relationship between the CYP2C19 genotypes and either CLOM or DCLOM levels does not show a clear trend ( Table 5 ). The MR CLOM/DCLOM for subgroup CYP2C19*2/*2 was significantly different from the MR CLOM/DCLOM for CYP2C19*1/*1 (Table 5; Figure 2 ). However, daily dose was relatively high for this subgroup. The homozygous presence of CYP2C19*17 was significantly associated with higher proportions of patients with CLOM levels below therapeutic range (Table 5 ). However, daily dose was relatively low for this subgroup. Within the CYP2D6*1/*1 subgroup, the differences in daily dose reached significance for subgroup CYP2C19*17/*17 compared with CYP2C19*1/*1 (data not shown). CYP2D6 genotype has been correlated in earlier studies with CLOM metabolism. [25] [26] [27] In this study, CYP2D6 genotype was significantly associated with MR CLOM/DCLOM ;
increasing SGD values correlated with decreasing MR CLOM/DCLOM values (see Supplementary Appendix E). However, even within the separate CYP2D6 genotype subgroups, no additional significant differences in CLOM levels, DCLOM levels, MR CLOM/DCLOM values, or C/D values were observed between the different CYP2C19 genotypes (data not shown).
ASCOC values for CYP2C19*2 and CYP2C19*17 In the SGD system described by Steimer et al., 3 the SGD value of CYP2D6 alleles is based on the allele-specific change of concentration on identical background (ASCOC). We calculated the ASCOC values of CYP2C19 alleles for the data collected on AMI, CIT, and CLOM (Table 6) . Positive values, indicating decreased metabolic activity, were observed for CYP2C19*2 for all genotype comparisons, with similar average values for AT, CIT, and CLOM ( þ 21, þ 18 and þ 18%, respectively). Negative values, indicating increased metabolic activity, were observed for CYP2C19*17 for most genotype comparisons, with similar average values for AT, CIT, and CLOM (À11, À10, and À8%). These individual differences in concentration were not significant, except one. Combining all data for each antidepressant, the ASCOC Number of subjects is restricted to subjects for which information on daily dose was available. Number of subjects is restricted to subjects for which information on daily dose was available.
b
Significantly different from CYP2C19 subgroup CYP2C19*1/*1 (Po0.05).
CYP2C19*17 and metabolism of antidepressants
A de Vos et al value for CYP2C19*2 was significantly higher than 0% for CIT and CLOM. Combining all data for all three antidepressants, the ASCOC was significantly higher than 0% for CYP2C19*2, and significantly lower than 0% for CYP2C19*17.
Discussion
CYP2C19 is involved in the metabolism of several antidepressants, including AT, CIT, and CLOM ( Figure 1 ). Serum levels indicate large interindividual differences in CYP2C19 activity. These differences are to some extend explained by the occurrence of the non-functional alleles CYP2C19*2 and CYP2C19*3. The impact of CYP2C19*2 on the metabolism of CYP2C19-dependent antidepressants is supported in this study by the association of CYP2C19*2 with increased AT and CIT levels and increased MR AT/NT and MR CIT/DCIT values. These data also support the assumption that CYP2C19 has clinically relevant activity toward the parent compounds AT and CIT. Earlier studies have shown that the CYP2C19*17 allele increases CYP2C19 activity toward omeprazole, imipramine and es-CIT. [12] [13] [14] 32 Sim et al. 11 have shown with an electrophoretic mobility shift assay that CYP2C19*17 introduces an extra transcription factor-binding site in the promotor region of CYP2C19, resulting in an increased CYP2C19 enzyme activity in vitro. We observed significant associations between CYP2C19*17 and lower MR for AT and CIT, but not CLOM. The majority of other parameters concerning AT and CIT metabolism show no significant associations with CYP2C19*17. Nevertheless, they do show a trend toward lower levels of parent drug. These data support the function of CYP2C19*17 in CIT metabolism, and indicate an effect of CYP2C19*17 on AT metabolism. The combined data on CYP2C19*17 and CLOM metabolism (in particular, the total ASCOC value and proportion of subjects below therapeutic range) might indicate a minor effect of CYP2C19*17 on CLOM metabolism. However, this effect is more likely caused by the significantly lower daily dose and lower mean age of the CYP2C19*17/*17 subgroup. We do not know the reason for the lower mean age in the CYP2C19*17/*17 subgroup. The more evident association between AT and CIT metabolic parameters and CYP2C19*2, compared with CYP2C19*17, could be caused by a smaller relative effect of CYP2C19*17 on CYP2C19 activity. This is reflected in the smaller ASCOC values obtained for CYP2C19*17. In earlier studies, an SGD value of 0 and 1 has been assigned to CYP2C19*2 and CYP2C19*1, respectively. On the basis of the smaller effect of CYP2C19*17, we propose an SGD value of 1.5 for CYP2C19*17. The genotype subgroup CYP2C19*2/*17 would then be appointed an SGD value of 1.5, predicting lower CYP2C19 activity compared with CYP2C19*1/*1. The MR data for AT and CIT did indeed indicate lower CYP2C19 activity for CYP2C19*2/*17 compared with CYP2C19*1/*1, as did the C/D data for CIT. The restricted number of significant associations between CYP2C19*2 or CYP2C19*17 and metabolic parameters is likely due to the presence of alternative metabolic pathways. CYP2D6 is one of the enzymes involved in the metabolic pathways for AT, CIT, and CLOM. Its influence is shown in this study by the significant associations between CYP2D6 genotype and parent drug levels or metabolite levels. The combination of decreasing NT levels with increasing SGD values, but no correlation with AT levels, supports the involvement of CYP2D6 in AT metabolism as depicted in Figure 1 . Similarly, the association of CYP2D6 genotype with CIT and DCIT levels supports the involvement of CYP2D6 genotype in both CIT and DCIT degradation. According to published data, CYP2D6 hydroxylates both CLOM and DCLOM (Figure 1) . [25] [26] [27] The involvement of CYP2D6 genotype in CLOM degradation is not supported by the present data, but the data do support the indicated metabolism of DCLOM.
Clinical relevance of CYP2C19*17
On the basis of relative serum levels, dose recommendations can be provided for specific genotype groups. 4, 33, 34 However, the clinical benefit of dose adjustments depends on both the extend of deviation in serum levels and the CYP2C19*17 and metabolism of antidepressants dose-response relationship. As suggested earlier, 14 the CYP2C19*17 allele might be associated with sub-therapeutic levels for those drugs that are extensively metabolized by CYP2C19. AT, CIT, and CLOM were selected as commonly used antidepressants being metabolized by CYP2C19. For AT, CYP2C19 genotype did affect the ratio of AT and NT levels, but not the sum of AT and NT levels. This is reflected in the lack of association of CYP2C19 genotype with daily dose and with AT þ NT levels outside therapeutic range. Consequently, CYP2C19*17 genotyping is not likely to be clinically relevant in AT therapy. Caution might be necessary with respect to NT levels, as CYP2C19*17 is associated with higher proportion of patients with NT levels above therapeutic range. With respect to CLOM, no clear associations were observed between CYP2C19 genotype and CLOM levels, likely because of the small contribution of CYP2C19 to overall CLOM metabolism. Therefore, CYP2C19*17 genotyping is not likely to improve response to CLOM therapy either. The CYP2C19*17 allele was significantly associated with lower proportions of patients with CIT levels above therapeutic range, and a non-significant increase in proportion of patients at sub-therapeutic range. However, the correlation between CIT levels and CYP2C19 was not significant, likely because 450% is metabolized by other enzymes. 31 Furthermore, a flat dose-response curve has been observed for the relationship between dose (or CIT levels) and response. Consequently, CYP2C19*17 genotyping is not likely to improve response to CIT therapy significantly. 35, 36 In conclusion, the data do not support routinely screening for CYP2C19*17 for patients using AT, CIT, or CLOM. Nevertheless, CYP2C19*17 could provide an explanation whenever physicians notice lower than expected serum levels of CYP2C19-dependent drugs and help exclude non-compliance of patients. From an academic point of view, information on the presence of CYP2C19*17 might prove useful in research related to the metabolism of CYP2C19-dependent drugs.
